Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile Marcos Cruces Olivar, Allan D. Burboa, Yolanda M. Gómez

Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting Sara Marsal Barril, Mª Auxiliadora Martin-Martinez, Francisco Javier Blanco-Garcia, Antonio Fernández-Nebro, Rosario García de Vicuña, Jesús Tornero-Molina, Fernando Sánchez-Alonso, Marta Novella-Navarro, Alejandro Escudero-Contreras, Juan José Alegre-Sancho, Ana Urruticoechea-Arana, Maria Sagrario Bustabad-Reyes, Pilar Trenor-Larraz, Trinidad Pérez-Sandoval, Maria Isabel Tevar-Sánchez, Jesús T. Sánchez-Costa, Enrique Raya-Álvarez

Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: Influential factors on price Mariángeles González Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gayá, Alicia Herrero, Alejandro Balsa